Setting bioequivalence requirements for drug development based on preclinical data: optimizing oral drug delivery systems.
The recently proposed Biopharmaceutics Classification System can be used to classify drugs and set standards for scale-up and post-approval changes as well as standards for in vitro/in vivo correlation for immediate and controlled release products. This classification scheme is based on determining the underlying process that is controlling the drug absorption rate and extent, namely, drug solubility and intestinal membrane permeability. Theoretical analysis and experimental results suggest that a permeability/solubility classification scheme can be used to set more rationale drug standards. In particular, high solubility/high permeability, rapidly dissolving drugs may be regulated on the basis of a single point rapid dissolution test while low solubility dissolution rate limited drugs can be regulated based on an in vitro dissolution test that reflects the in vivo dissolution process. This dissolution test may include multiple time points, media change, as well as surfactants in order to reflect the in vivo dissolution process and would be used by the manufacturer for requesting a waiver from a bioequivalence (BE) trial. For controlled release products, the regulation of bioequivalence standards is more complex due to the potential differences in position-dependent permeability/solubility and metabolism of drugs along the gastrointestinal tract. These differences may result in drug absorption rates that are highly transit time dependent. This paper will present the current status of the biopharmaceutic drug classification scheme, the underlying developed data base and its application to optimizing IR and CR products.
Lipka
E
E
TSRL, Inc. 540 Avis Drive, Suite A, Ann Arbor, MI 48108, USA. elipka@tsrlinc.com
Amidon
G L
GL
D000284:Administration, Oral; D016208:Databases, Factual; D004304:Dosage Forms; D016503:Drug Delivery Systems; D004341:Drug Evaluation; D006801:Humans; D007408:Intestinal Absorption; D010539:Permeability; D004364:Pharmaceutical Preparations; D012995:Solubility; D013810:Therapeutic Equivalency
D004304:Dosage Forms; D004364:Pharmaceutical Preparations